Business Context and Reporting Period
Envveno Medical Corp (NVNO) filed a Form 8-K on January 20, 2026, reporting a corporate action effective as of 12:01 a.m. Eastern Standard Time on that date. The company is incorporated in Delaware and trades on The NASDAQ Stock Market LLC.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on capital structure adjustments.
- Pre-Split Outstanding Shares: 22,946,223
- Post-Split Outstanding Shares: 655,606
- Authorized Shares: 250,000,000 (unchanged)
- Par Value: $0.00001 per share (unchanged)
Material Changes
The primary material change is the implementation of a one-for-thirty-five (1:35) reverse stock split. Every 35 shares of issued and outstanding common stock were combined into one share. Fractional shares resulting from the split were rounded up to the nearest whole share. Consequently, the total number of outstanding shares was reduced by approximately 97.15%.
Outstanding stock options and warrants were proportionally adjusted: the number of shares underlying these securities was reduced by a factor of 35, and exercise prices were increased by a factor of 35.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclaimers regarding the Certificate of Amendment. The company confirmed that trading began on a reverse stock split-adjusted basis on January 20, 2026. Equiniti Trust Company, LLC serves as the exchange agent.
Investor Verification Checklist
- Verify the adjusted share count and exercise prices for any held options or warrants.
- Confirm the post-split trading price on NASDAQ to ensure proper broker adjustment.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional charter changes.
- Check for subsequent filings regarding the company's liquidity status, as reverse splits are often associated with compliance efforts.